Novel EGFR Inhibitors against Resistant L858R/T790M/C797S Mutant for Intervention of Non-Small Cell Lung Cancer

To overcome C797S mutation, the latest and most common resistance mechanism in the clinical treatment of third-generation EGFR inhibitor, a novel series of substituted 6-(2-aminopyrimidine)-indole derivatives were designed and synthesized. Through the structure-activity relationship (SAR) study, compound 11eg was identified as a novel and potent EGFR